| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2803087101015 | 308710101 | CARICIA F.C.TAB 5MG/TAB BTx28 (2x14) σε PVC/ALU foil blisters | 10.32 | 10.83 | 14.92 |
| 05/2018 | 2803087102012 | 308710201 | CARICIA F.C.TAB 10MG/TAB BTx28 (2x14) σε PVC/ALU foil blisters | 15.42 | 16.18 | 22.29 |
For the palliative treatment of mild to moderate dementia of the Alzheimer's type.
Donepezil is a piperidine derivative that is a centerally active, reversible inhibitor of acetylcholinesterase. This drug is structurally unrelated to other anticholinesterase agents. Donepezil's proposed mechanism of action involves the reversible inhibition of cholinesterases (eg. acetylcholinesterase), which prevents the hydrolysis of acetycholine, and leads to an increased concentration of acetylcholine at cholinergic synapses. Evidence suggests that the anticholinesterase activity of donepezil is relatively specific for acetylcholinesterase in the brain.
Symptoms of overdose include severe nausea, vomiting, salivation, sweating, bradycardia, hypotension, respiratory depression, collapse and convulsions. Increasing muscle weakness is a possibility and may result in death if respiratory muscles are involved.
Donepezil is well absorbed with a relative oral bioavailability of 100% and reaches peak plasma concentrations in 3 to 4 hours.
70 hours
Donepezil is both excreted in the urine intact and extensively metabolized to four major metabolites, two of which are known to be active, and a number of minor metabolites, not all of which have been identified.
* 12 L/kg
* apparent plasma cl=0.13 L/hr/kg